<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The level of CD20-expression in patients with B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (B-CLL) is low in comparison to other B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> B-cells </plain></SENT>
<SENT sid="2" pm="."><plain>Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (B-<z:chebi fb="1" ids="53412">PLL</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>We could not identify any correlation between CD20-expression and efficacy of rituximab treatment </plain></SENT>
</text></document>